These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 2495709)
41. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. Collen D; Stassen JM; Verstraete M J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615 [TBL] [Abstract][Full Text] [Related]
43. Fibrinolytic effects of pro-urokinase combined with low-dose urokinase compared to high-dose urokinase in patients with acute myocardial infarction. Pindur G; Koehler M; Sen S; Hermes R; Miyashita C; Wenzel E; Schieffer H Thromb Res; 1992 Jul; 67(2):191-200. PubMed ID: 1279835 [TBL] [Abstract][Full Text] [Related]
44. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Lincoff AM; Topol EJ; Califf RM; Sigmon KN; Lee KL; Ohman EM; Rosenschein U; Ellis SG Am J Cardiol; 1995 May; 75(14):871-6. PubMed ID: 7732992 [TBL] [Abstract][Full Text] [Related]
45. Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction. Tranchesi B; Bellotti G; Chamone DF; Verstraete M Am J Cardiol; 1989 Jul; 64(3):229-32. PubMed ID: 2500842 [No Abstract] [Full Text] [Related]
46. [Coronary thrombolysis with urokinase and t-PA--comparison of intracoronary thrombolysis and intravenous coronary thrombolysis]. Motomiya T Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):782-9. PubMed ID: 12436616 [No Abstract] [Full Text] [Related]
47. Patency trials with reteplase (r-PA): what do they tell us? Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406 [TBL] [Abstract][Full Text] [Related]
48. A randomized study of prourokinase during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. Geng W; Zhang Q; Liu J; Tian X; Zhen L; Song D; Yang Y; Meng H; Wang Y; Chen J J Interv Cardiol; 2018 Apr; 31(2):136-143. PubMed ID: 29171086 [TBL] [Abstract][Full Text] [Related]
49. Efficacy of intracoronary and intravenous urokinase in acute myocardial infarction. Cernigliaro C; Sansa M; Campi A; Bongo AS; Carfora A; Rossi P G Ital Cardiol; 1984 Nov; 14(11):927-30. PubMed ID: 6526208 [TBL] [Abstract][Full Text] [Related]
50. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia. Yang Y; Li Q; Miyashita H; Howlett W; Siddiqui M; Shuaib A J Neurosurg; 2000 May; 92(5):841-7. PubMed ID: 10794299 [TBL] [Abstract][Full Text] [Related]
51. Influence of different start time of urokinase therapy after acute myocardial infarction efficacy of thrombolysis. The Collaborative Research Group on Thrombolysis. Chin Med J (Engl); 1997 Jan; 110(1):47-9. PubMed ID: 9594321 [TBL] [Abstract][Full Text] [Related]
52. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Matsuo O; Rijken DC; Collen D Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339 [TBL] [Abstract][Full Text] [Related]